NCT04317469

Brief Summary

In this prospective study of 60patients, we tested the hypothesis That markedly elevated levels of plasma von Willebrand factor (VWF) a marker of endothelial cell injury might predict the development of acute respiratory distress syndrome (A.R.D.S) in risky patients. We compared our result to IL.6 as control biomarker for A.R.D.S development. Acute lung injury was quantified on two -point scoring system (Berlin definition of ARDS and Murray score of acute lung injury). Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Mar 2020

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 18, 2020

Completed
3 days until next milestone

Study Start

First participant enrolled

March 21, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 23, 2020

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 20, 2021

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 20, 2021

Completed
Last Updated

March 23, 2020

Status Verified

March 1, 2020

Enrollment Period

12 months

First QC Date

March 18, 2020

Last Update Submit

March 19, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • level of vwf at 72 hours

    Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).

    72 hours

Study Arms (2)

ARDS group ,

Diagnostic Test: VWF measurement

non ARDS group

Diagnostic Test: VWF measurement

Interventions

VWF measurementDIAGNOSTIC_TEST

Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).

Also known as: IL6 measurement
ARDS group ,non ARDS group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

60 patients, admitted to the ICUs, staying \>24 hrs will be randomly assigned to enter this study.

You may qualify if:

  • Patients between 18 and 80 years old of both sexes.
  • risk factor for development of acute respiratory distress syndrome or acute lung injury either by:
  • Direct lung injury includes: Severe pneumonia (infection), Breathing a vomited stomach contents (aspiration), Breathing harmful fumes or smoke, severe trauma to the chest or other accident that bruises the lungs.
  • Indirect lung injury includes: sepsis, Severe injury or trauma with shock, blood transfusions , drug overdose acute pancreatitis, fracture of the long bones, near drowning ,anaphylaxis, uremia, fat embolus , and intracranial insult.

You may not qualify if:

  • (1) pregnancy;
  • (2) a preexisting medical condition with a life expectancy less than 3 months
  • (3) evidence of cardiogenic pulmonary edema
  • (4) age under 18 years old or above 80 years old
  • (5) late stages of liver cell failure, renal failure
  • (6) severe myocardial infarction
  • (7) deep coma.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Respiratory Distress Syndrome

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesRespiration Disorders

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant professor of anesthiology and ICU , faculty of medicine , Ain Shams univeristy

Study Record Dates

First Submitted

March 18, 2020

First Posted

March 23, 2020

Study Start

March 21, 2020

Primary Completion

March 20, 2021

Study Completion

September 20, 2021

Last Updated

March 23, 2020

Record last verified: 2020-03